BEAM
Beam TherapeuticsBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
The core bull case is still program-driven rather than quarter-driven: BEAM-302 now has a defined pivotal path, risto-cel has increasingly mature clinical and operational data, and February financing reduced near-term balance-sheet pressure. As of May 4, 2026, Beam’s investor site still did not show a confirmed Q1 2026 earnings release or earnings 8-K, so the thesis remains anchored to prior primary-source program updates rather than fresh quarterly commentary [#IR-2026-05-04].
Posture
Constructive
Lead driver
Momentum
What changed
1 setup hits (3d) with net bullish as of 2026-06-02.
What can break
As of May 4, 2026, Beam’s investor-relations pages still showed April 1, 2026 as the latest press release and March 25, 2026 as the latest webcast, so a Q1 2026 earnings release or earnings 8-K was not confirmed in primary sources [#IR-2026-05-04].
Momentum
76
Value
41
Sentiment
66
Setup hits (3d)
1 · Net Bullish
AI TargetsBase $35.00 · Bull $46.00 · Bear $22.00
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-04 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Bullish
Target $48.13
Why
Momentum76 · Δ7d +6.2
Value41 · Δ7d +0.1
Sentiment66 · Δ7d -6.5
So what
Strength-led posture (Net Bullish). Favor watchlist adds and disciplined entries.
Lead driver: Momentum · See technicals
Momentum
76
34% active weight
Current posture
7d trendSoftening
Δ7d
+6.2
Δ21d
-14.0
Value
41
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.2
Sentiment
66
33% active weight
Current posture
7d trendSoftening
Δ7d
-6.5
Δ21d
+10.3
Why this grade
Composite grade B. Momentum 76.0 / Value 41.1 / Sentiment 66.0
Fundamentals (TTM)As of 2026-06-01
Fundamentals (TTM)
As of 2026-06-01
Market Cap
$3.2B
Beta
2.12
Shares Out
101.47M
P/E (TTM) · Derived
-39.0
P/S (TTM)
48.90
P/FCF (TTM) · Derived
-8.41
Rev YoY
-32.0%
EPS YoY
+6.3%
Gross Margin
-
Op Margin
-837.1%
Net Debt
-$850.74M
Current Ratio
6.02
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology